Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||BAZ2-ICR + BI-9564 + JQ1|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BAZ2-ICR||BAZ2-ICR is a selective BAZ2A and BAZ2B bromodomain inhibitor, which has potential antitumor activity (PMID: 25719566, PMID: 31000582).|
|BI-9564||BI9564|BI 9564||BI-9564 is a selective BRD9 inhibitor that also has activity against BRD7 and CECR2, which has potential antitumor activity (PMID: 31000582, PMID: 26749027, PMID: 26914985).|
|JQ1||JQ-1||BET Inhibitor (Pan) 30||JQ1 is a BET bromodomain inhibitor with greatest specificity towards BRD4, resulting in decreased Myc expression, increased cell death, reduced macrophage immunosuppression, and inhibition of tumor growth (PMID: 24231268, PMID: 31018997, PMID: 30906568, PMID: 32800944).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||BAZ2-ICR + BI-9564 + JQ1||Preclinical - Cell culture||Actionable||In a preclinical study, BAZ2-ICR treatment combined with BI-9564 and JQ1 inhibited Rb1 phosphorylation, induced senescence and complete growth inhibition, and led to enhanced cell cycle arrest in triple-negative breast cancer cell lines in culture (PMID: 31000582).||31000582|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|